GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Glucagon-like peptide 1 (GLP-1) receptor agonists are a new group of antidiabetic medications quickly gaining popularity. We aimed to examine behavioural and neuroendocrine changes following chronic treatment with GLP-1 receptor agonists in animal models. Methods: The effects of chronic treatment with GLP-1 receptor agonists were determined on behavioural parameters [anxiety level in the light–dark compartment test, the motor activity in automated activity cages, immobility in the forced swimming test (FST)] and on corticosterone release in mice. The possible antidepressant effect of chronic liraglutide treatment was also studied in Flinders Sensitive Line (FSL) rats, a genetic model of depression. Results: Two weeks of treatment with exenatide (10 µg /kg twice daily) or liraglutide (1200 µg/kg once daily) did not affect the anxiety level in a light–dark compartment test nor induce an antidepressant-like effect in the FST in mice. Moreover, chronic treatment with liraglutide had no effect on depression-related behaviour in FSL rats. Interestingly, hypolocomotion induced by the drugs in mice disappeared after chronic dosing. Both of the GLP-1 receptor agonists induced robust increases in corticosterone levels in mice under basal conditions as well as in the case of combination with swimming stress. Remarkably, exenatide was as potent a stimulator of corticosterone release after 2 weeks as after acute administration. Conclusions: The increases in corticosterone release seen after acute exenatide or liraglutide treatment do not abate after 2 weeks of treatment demonstrating that tolerance does not develop towards this particular effect of GLP-1 agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 1×
“Thus, the nausea induced by peripheral administration of GLP-1 or exenatide (a GLP-1 agonist) seems to be caused by its direct action in certain brain regions (6,7); and some effects of the drug are mediated by the vagal afferents (8).”
The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207 · cited 1×
“Moreover, it has been demonstrated several times that peripherally administered GLP-1 receptor agonists may influence memory formation and retrieval (3,9), and a recent study demonstrated that a GLP-1 receptor agonist was able to attenuate the reinforcing properties of alcohol in rodents (10).”
MacLusky, N. J., Cook, S., Scrocchi, L., Shin, J., Kim, J., Vaccarino, F., Asa, S. L., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.2.7326 · Cited by 133
Punjabi, M., Arnold, M., Rüttimann, E., Graber, M., Geary, N., Pacheco-López, G., & Langhans, W. (2014) · Endocrinology · doi:10.1210/en.2013-1447 · Cited by 59
McKay, N. J., & Daniels, D. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12086 · Cited by 37
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Peripheral administration of exendin-4 or liraglutide increase circulating corticosterone in mice under basal conditions and also during a forced swimming test [818].”
BackgroundAnxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Several animal studies have been undertaken with two studies showing that chronic treatment in rats is associated with reversal of depression-like behavior and acute treatment induced anxiety-like behavior (270, 272), while an alternate study indicated no GLP-1 induced changes in either behavior (273).”
ResultAnderberg, R. H., Richard, J. E., Hansson, C., Nissbrandt, H., Bergquist, F., & Skibicka, K. P. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.021 · Cited by 170
Guerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Heinla, K., Vasar, E., Reppo, I., Sedman, T., & Volke, V. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01381-w · Cited by 30
Self-citationLi, S., Sabbah, S. G., Kwan, A. T. H., & McIntyre, R. S. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.08.002 · Cited by 19
Metadata
- Authors
- Krass, M., Volke, A., Rünkorg, K., Wegener, G., Lund, S., Abildgaard, A., Vasar, E., & Volke, V.
- Venue
- Acta Neuropsychiatrica
- Publisher
- Cambridge University Press (CUP)
- Published
- 2014-12-03
- Volume
- 27
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0924-2708 (ISSN-L)
- 1601-5215
- OpenAlex
- W2332387004
- Cited by
- 27
- References
- 6
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.